Sera Prognostics Reports Positive Top-line AVERT PRETERM TRIAL Data

(24/7 MARKET NEWS) – Sera Prognostics Inc. (NASDAQ:SERA) reported, this morning, top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. Sera Prognostics stated that its PreTRM® test-and-treat strategy demonstrated statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay

Sera Prognostics is at $1.66, up $0.35 (26.71%), on trading volume of 670 thousand premarket shares.

Its 52-week trading range is $1.10 to $7.215. It’s cleared several months of resistance and is set up for a potential run higher.

View original content:  

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.